SCHEMBL6328368

SCHEMBL6328368

COc1ccccc1-c1noc(CCC(=O)O)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.67
GAA P10253 4/20 0.67
L3MBTL1 Q9Y468 3/20 0.67
HPGD P15428 2/20 0.67
ALOX15 P16050 2/20 0.67
HSD17B10 Q99714 2/20 0.67
LMNA P02545 4/20 0.63
MAPT P10636 3/20 0.62
ATM Q13315 1/20 0.62
CYP3A4 P08684 1/20 0.61
SMN1; SMN2 Q16637 4/20 0.60
GLA P06280 1/20 0.60
RXRA P19793 1/20 0.59
TSHR P16473 2/20 0.58
AKR1B1 P15121 1/20 0.56
TP53 P04637 2/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
HTT P42858 1/20 0.54
MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3046287 0.91 L3MBTL1 (0.62) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL6331512 0.89 LMNA (0.58) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL7977048 0.89 ALDH1A1 (0.66) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL7977046 0.89 ALDH1A1 (0.66) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL6325652 0.87 LMNA (0.64) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL6324047 0.85 ALDH1A1 (0.59) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL6327861 0.85 ALDH1A1 (0.59) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL6325724 0.84 LMNA (0.68) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL6325644 0.84 LMNA (0.68) ALDH1A1GAAL3MBTL1HPGDALOX15
SCHEMBL3045660 0.83 L3MBTL1 (0.64) ALDH1A1GAAL3MBTL1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed
WO-2001007409-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS ASTRAZENECA UK LIMITED (GB) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 ALDH1A1 338/4885GAA 2424/4885L3MBTL1 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.